Today's Rundown Featured Story | | | Wednesday, November 28, 2018 Companies have been piling into the nonalcoholic steatohepatitis (NASH) space lately, and Genentech is no exception. The biotech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount. |
|
|
Top Stories Wednesday, November 28, 2018 A Chinese researcher has claimed to be the first to use CRISPR gene-editing tools on live, implanted human embryos, resulting in the birth of twin girls and swift international backlash over the ethics of the procedure. Tuesday, November 27, 2018 Kronos Bio, a member of this year’s Fierce 15, has snagged Regeneron Pharmaceuticals’ executive director of business development, Philip Gutry, to serve as its new chief business officer—tasking him with managing the company’s clinical alliances and expanding its pipeline. Monday, November 26, 2018 A diagnosis of chronic lymphocytic leukemia (CLL) can mean a long road with many twists and turns as patients try to achieve long-term remission from this chronic, complex and progressive form of blood cancer. Wednesday, November 28, 2018 Hookipa Pharma has teamed up with DarwinHealth to identify shared self-antigens for multiple tumor subtypes. The collaboration is expected to yield antigens with validated immunogenicity that Hookipa can use as the basis for immunotherapies. Wednesday, November 28, 2018 Prometic Life Sciences has entered into an agreement to sell up to $50 million in stock over the next 16 months. The agreement gives Prometic a way to trickle cash into its bank account while working to escape its current financial pressures. Wednesday, November 28, 2018 Vedanta Biosciences’ three-year-old collaboration with Johnson & Johnson on microbiome therapies has moved to the clinical stage, triggering a $12 million milestone payment. Wednesday, November 28, 2018 Roche launched a new automated in vitro diagnostic to detect tropomyosin receptor kinase proteins in cancer, which the company hopes will have potential use in a range of solid tumor types and site-agnostic targeted therapies—such as Bayer and Loxo Oncology’s newly approved pancancer drug, Vitrakvi. | This week's sponsor is Johnson & Johnson Innovation. | |  | |
Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. | 
